A phase 3 cardiovascular outcome trial (HORIZON trial; ClinicalTrials.gov Identifier: NCT04023552) with pelacarsen is currently ongoing in patients with elevated baseline Lp(a) levels (>70 mg/dL) and established ASCVD (a prior history of myocardial infarction, ischemic stroke, or symptomatic peripheral artery disease). This evidence concerns the gene LPA and peripheral arterial disease.